Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 5-20

  Pintér, Erika ^a   Pozsgai, Gábor ^a   Hajna, Zsõfia ^a   Helyes, Zsuzsanna ^a   Szolcsányi, János ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

calcitonin gene related peptide; cortistatin; galanin; pituitary adenylate cyclase activating polypeptide; somatostatin; tachykinin

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 IODOBENZYLAMINO)QUINUCLIDINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; ADRENOMEDULLIN; APREPITANT; CORTISTATIN; CYTOKINE; DEXAMETHASONE; GALANIN; GHRELIN; HORMONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERMEDIN; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NOLPITANTIUM; OPIATE PEPTIDE; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; ROLAPITANT; SOMATOSTATIN; TACHYKININ; TACHYKININ RECEPTOR; UNINDEXED DRUG; UROCORTIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VOFOPITANT; ANTIINFLAMMATORY AGENT; AUTACOID;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ATOPIC DERMATITIS; BRAIN NERVE CELL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; DERMATITIS; DIABETIC NEUROPATHY; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEADACHE; HUMAN; HYPERALGESIA; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; LIPOPOLYSACCHARIDE-INDUCED AIRWAY INFLAMMATION; MALE; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PANCREATITIS; PELVIC INFLAMMATORY DISEASE; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; SEPSIS; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN; TRANQUILIZING ACTIVITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; RECEPTORS, NEUROPEPTIDE;

EID: 84891106934     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12097     Document Type: Article

References (173)

1. Maggi CA,. Tachykinins and calcitonin gene-related peptide (CGRP) as cotransmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995; 45: 1-98.
2. Pernow B,. Substance P-a putative mediator of antidromic vasodilation. Gen Pharmacol 1983; 14: 13-16.
3. Longmore J, Hill RG, Hargreaves RJ,. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol 1997; 75: 612-621.
4. Graham GJ, Stevens JM, Page NM, Grant AD, Brain SD, Lowry PJ, Gibbins JM,. Tachykinins regulate the function of platelets. Blood 2004; 104: 1058-1065.
5. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, Candenas ML,. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11: 2045-2081.
6. Zaratin P, Angelici O, Clarke GD, Schmid G, Raiteri M, Carità F, Bonanno G,. NK3 receptor blockade prevents hyperalgesia and the associated spinal cord substance P release in monoarthritic rats. Neuropharmacology 2000; 39: 141-149.
7. Veron M, Guenon I, Nenan S, Emonds-Alt X, Advenier C, Lagente V, Boichot E,. Interactions of tachykinin receptor antagonists with lipopolysaccharide- induced airway inflammation in mice. Clin Exp Pharmacol Physiol 2004; 31: 634-640.
8. Sanger GJ, Tuladhar BR, Bueno L, Furness JB,. Defensive and pathological functions of the gastrointestinal NK3 receptor. Vascul Pharmacol 2006; 45: 215-220.
9. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ,. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 2000; 1: 392-397.
10. Duffy RA, Hedrick JA, Randolph G, Morgan CA, Cohen-Williams ME, Vassileva G, Lachowicz JE, Laverty M, Maguire M, Shan LS, Gustafson E, Varty GB,. Centrally administered hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology 2003; 45: 242-250.
11. Metwali A, Blum AM, Elliott DE, Setiawan T, Weinstock JV,. Cutting edge: hemokinin has substance P-like function and expression in inflammation. J Immunol 2004; 172: 6528-6532.
12. Nelson DA, Bost KL,. Non-neuronal mammalian tachykinin expression. Front Biosci 2004; 9: 2166-2176.
13. Song H, Yin W, Zeng Q, Jia H, Lin L, Liu X, Mu L, Wang R,. Hemokinins modulate endothelium function and promote angiogenesis through neurokinin-1 receptor. Int J Biochem Cell Biol 2012; 44: 1410-1421.
14. Naono-Nakayama R, Sunakawa N, Ikeda T, Matsushima O, Nishimori T,. Subcutaneous injection of endokinin C/D attenuates carrageenan-induced inflammation. Peptides 2010; 31: 1767-1771.
15. Berger A, Paige CJ,. Hemokinin-1 has substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J Neuroimmunol 2005; 164: 48-56.
16. Kurtz MM, Wang R, Clements MK, Cascieri MA, Austin CP, Cunningham BR, Chicchi GG, Liu Q,. Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 2002; 296: 205-212.
17. Page NM,. Hemokinins and endokinins. Cell Mol Life Sci 2004; 61: 1652-1663.
18. Page NM,. Characterization of the gene structures, precursor processing and pharmacology of the endokinin peptides. Vascul Pharmacol 2006; 45: 200-208.
19. Endo D, Ikeda T, Ishida Y, Yoshioka D, Nishimori T,. Effect of intrathecal administration of hemokinin-1 on the withdrawal response to noxious thermal stimulation of the rat hind paw. Neurosci Lett 2006; 392: 114-117.
20. Snider RM, Constantine JW, Lowe JA 3rd, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, Hess HJ,. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991; 251: 435-437.
21. McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, Siok CJ, Lowe JA 3rd, Heym J,. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 1991; 251: 437-439.
22. Grady EF, Yoshimi SK, Maa J, Valeroso D, Vartanian RK, Rahim S, Kim EH, Gerard C, Gerard N, Bunnett NW, Kirkwood KS,. Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice. Br J Pharmacol 2000; 130: 505-512.
23. Landau AM, Yashpal K, Cahill CM, St Louis M, Ribeiro-da-Silva A, Henry JL,. Sensory neuron and substance P involvement in symptoms of a zymosan-induced rat model of acute bowel inflammation. Neuroscience 2007; 145: 699-707.
24. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, Hemmer B, Sommer N,. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist-a putative role for substance P in CNS inflammation. J Neuroimmunol 2006; 179: 1-8.
25. Makino A, Sakai A, Ito H, Suzuki H,. Involvement of tachykinins and NK1 receptor in the joint inflammation with collagen type II-specific monoclonal antibody-induced arthritis in mice. J Nippon Med Sch 2012; 79: 129-138.
26. Uematsu T, Sakai A, Ito H, Suzuki H,. Intra-articular administration of tachykinin NK1 receptor antagonists reduces hyperalgesia and cartilage destruction in the inflammatory joint in rats with adjuvant-induced arthritis. Eur J Pharmacol 2011; 668: 163-168.
27. 1)- Rezeptorantagonisten in der Schmerztherapie? Anaesthesist 2002; 51: 308-319.
28. Polley JS, Gaskin PJ, Perren MJ, Connor HE, Ward P, Beattie DT,. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regul Pept 1997; 68: 23-29.
29. Hong SK, Han JS, Min SS, Hwang JM, Kim YI, Na HS, Yoon YW, Han HC,. Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett 2002; 322: 21-24.
30. Lam FF, Ng ES,. Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol 2010; 159: 958-969.
31. Rijnierse A, van Zijl KM, Koster AS, Nijkamp FP, Kraneveld AD,. Beneficial effect of tachykinin NK1 receptor antagonism in the development of hapten-induced colitis in mice. Eur J Pharmacol 2006; 548: 150-157.
32. van der Kleij HP, Kraneveld AD, Redegeld FA, Gerard NP, Morteau O, Nijkamp FP,. The tachykinin NK1 receptor is crucial for the development of non-atopic airway inflammation and hyperresponsiveness. Eur J Pharmacol 2003; 476: 249-255.
33. Hirayama Y, Lei YH, Barnes PJ, Rogers DF,. Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pigs in vivo. Br J Pharmacol 1993; 108: 844-851.
34. Ursino MG, Vasina V, De Ponti F,. Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. Eur J Pharmacol 2009; 603: 133-137.
35. Reis RC, Brito HO, Fraga D, Cabrini DA, Zampronio AR,. Central substance P NK1 receptors are involved in fever induced by LPS but not by IL-1β and CCL3/MIP-1α in rats. Brain Res 2011; 1384: 161-169.
36. Cutrufo C, Evangelista S, Cirillo R, Ciucci A, Conte B, Lopez G, Manzini S, Maggi CA,. Effect of MEN 11467, a new tachykinin NK1 receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs. Eur J Pharmacol 1999; 374: 277-283.
37. Sakamoto T, Kamijima M, Miyake M,. Neurogenic airway microvascular leakage induced by toluene inhalation in rats. Eur J Pharmacol 2012; 685: 180-185.
38. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PL,. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995; 115: 84-94.
39. Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM,. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav 2012; 102: 95-100.
40. Ballard TM, Sänger S, Higgins GA,. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 2001; 412: 255-264.
41. Cheeta S, Tucci S, Sandhu J, Williams AR, Rupniak NM, File SE,. Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 2001; 915: 170-175.
42. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, Carey GJ, Coffin VL,. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002; 27: 371-379.
43. Varty GB, Cohen-Williams ME, Hunter JC,. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003; 14: 87-95.
44. Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF,. Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology 2008; 33: 1919-1928.
45. Hill R,. NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 244-246.
46. Urban LA, Fox AJ,. NK1 receptor antagonists-are they really without effect in the pain clinic? Trends Pharmacol Sci 2000; 21: 462-464.
47. Ebner K, Sartori SB, Singewald N,. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 2009; 15: 1647-1674.
48. Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, Reines S,. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2012; 20: 1-11.
49. Fahy JV, Wong HH, Geppetti P, Reis JM, Harris SC, Maclean DB, Nadel JA, Boushey HA,. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 879-884.
50. Ichinose M, Miura M, Yamauchi H, Kageyama N, Tomaki M, Oyake T, Ohuchi Y, Hida W, Miki H, Tamura G, Shirato K,. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 1996; 153: 936-941.
51. Diemunsch P, Joshi GP, Brichant J-F,. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth 2009; 103: 7-13.
52. Patel L, Lindley C,. Aprepitant-a novel NK1-receptor antagonist. Expert Opin Pharmacother 2003; 4: 2279-2296.
53. Curran MP, Robinson DM,. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009; 69: 1853-1878.
54. Navari RM,. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007; 16: 1977-1985.
55. Altorjay A, Melson T, Chinachoit T, Kett A, Aqua K, Levin J, Blackburn LM, Lane S, Pergolizzi JV Jr,. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg 2011; 146: 201-206.
56. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM,. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
57. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y,. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-392.
58. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan KR, Fernandes S,. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011; 31: 727-733. Erratum in: J Clin Psychopharmacol. 2012; 32: 185.
59. Elekes K, Helyes Z, Németh J, Sándor K, Pozsgai G, Kereskai L, Börzsei R, Pintér E, Szabõ A, Szolcsányi J,. Role of capsaicin-sensitive afferents and sensory neuropeptides in endotoxin-induced airway inflammation and consequent bronchial hyperreactivity in the mouse. Regul Pept 2007; 141: 44-54.
60. Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA,. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998; 12: 17-23.
61. Emonds-Alt X, Advenier C, Cognon C, Croci T, Daoui S, Ducoux JP, Landi M, Naline E, Neliat G, Poncelet M, Proietto V, Van Broeck D, Vilain P, Soubrié P, Le Fur G, Maffrand JP, Brelière JC,. Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist. Neuropeptides 1997; 31: 449-458.
62. Cutrufo C, Evangelista S, Cirillo R, Ciucci A, Conte B, Lopez G, Manzini S, Maggi CA,. Protective effect of the tachykinin NK2 receptor antagonist nepadutant in acute rectocolitis induced by diluted acetic acid in guinea-pigs. Neuropeptides 2000; 34: 355-359.
63. Lecci A, Carini F, Tramontana M, D'Aranno V, Marinoni E, Crea A, Bueno L, Fioramonti J, Criscuoli M, Giuliani S, Maggi CA,. Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models. J Pharmacol Exp Ther 2001; 299: 247-254.
64. Ramalho R, Soares R, Couto N, Moreira A,. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011; 11: 41. DOI: 10.1186/1471-2466-11-41.
65. Joos GF, Van Schoor J, Kips JC, Pauwels RA,. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996; 153: 1781-1784.
66. Joos GF, Vincken W, Louis R, Schelfhout VJ, Wang JH, Shaw MJ, Cioppa GD, Pauwels RA,. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004; 23: 76-81.
67. Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, Cohen J, Sterk PJ, Miller B, Paccaly A, Burggraaf J, Cohen AF, Diamant Z,. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007; 175: 450-457.
68. Schelfhout V, Van De Velde V, Maggi C, Pauwels R, Joos G,. The effect of the tachykinin NK(2) receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmatics. Ther Adv Respir Dis 2009; 3: 219-226.
69. Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A,. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1311-1321.
70. Schelfhout V, Louis R, Lenz W, Heyrman R, Pauwels R, Joos G,. The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulm Pharmacol Ther 2006; 19: 413-418.
71. Brain SD, Cox HM,. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006; 147 (Suppl. 1): S202-211.
72. Barwell J, Wootten D, Simms J, Hay DL, Poyner DR,. RAMPs and CGRP receptors. Adv Exp Med Biol 2012; 744: 13-24.
73. Hay DL,. What makes a CGRP2 receptor? Clin Exp Pharmacol Physiol 2007; 34: 963-971.
74. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-1110.
75. Hoffmann J, Goadsby PJ,. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol 2012; 14: 50-59.
76. Said SI, Mutt V,. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169: 1217-1218.
77. Said SI, Rosenberg RN,. Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science 1976; 192: 907-908.
78. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH,. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-574.
79. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A,. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 1990; 170: 643-648.
80. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H,. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009; 61: 283-357.
81. Németh J, Reglodi D, Pozsgai G, Szabõ A, Elekes K, Pintér E, Szolcsányi J, Helyes Z,. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice. Neuroscience 2006; 143: 223-230.
82. Gonzalez-Rey E, Delgado M,. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci 2007; 28: 482-491.
83. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M,. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol 2001; 167: 3182-3189.
84. Deng S, Xi Y, Wang H, Hao J, Niu X, Li W, Tao Y, Chen G,. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010; 265: 105-110.
85. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, Gomariz RP, Leceta J, Waschek JA,. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2009; 106: 2012-2017.
86. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Martin J, Pozo D, Ganea D, Delgado M,. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann N Y Acad Sci 2006; 1070: 276-281.
87. Nemetz N, Abad C, Lawson G, Nobuta H, Chhith S, Duong L, Tse G, Braun J, Waschek JA,. Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int J Cancer 2008; 122: 1803-1809.
88. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP,. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124: 961-971.
89. Chorny A, Delgado M,. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008; 172: 1297-1307.
90. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, Brabet P, Leceta J, Gomariz RP,. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 2002; 99: 1053-1058.
91. Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT, Nawata H,. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 2005; 30: 62-70.
92. Sakurai Y, Shintani N, Arimori A, Hamagami K, Higuchi N, Inoue H, Ikeda K, Hayata A, Hashimoto H, Baba A,. Cerulein-induced acute pancreatitis in PACAP knockout mice. J Mol Neurosci 2011; 43: 8-15.
93. Martínez C, Juarranz Y, Abad C, Arranz A, Miguel BG, Rosignoli F, Leceta J, Gomariz RP,. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. J Leukoc Biol 2005; 77: 729-738.
94. Juarranz Y, Gutiérrez-Cañas I, Arranz A, Martínez C, Abad C, Leceta J, Pablos JL, Gomariz RP,. VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts. Ann N Y Acad Sci 2006; 1070: 359-364.
95. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT, Waschek JA,. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2010; 107: 19555-19560.
96. Schytz HW, Holst H, Arendt-Nielsen L, Olesen J, Ashina M,. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. J Headache Pain 2010; 11: 309-316.
97. Schytz HW,. Investigation of carbachol and PACAP38 in a human model of migraine. Dan Med Bull 2010; 57: B4223.
98. Markovics A, Kormos V, Gaszner B, Lashgarara A, Szoke E, Sandor K, Szabadfi K, Tuka B, Tajti J, Szolcsanyi J, Pinter E, Hashimoto H, Kun J, Reglodi D, Helyes Z,. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis 2012; 45: 633-644.
99. Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S,. The melanocortin system in control of inflammation. ScientificWorldJournal 2010; 10: 1840-1853.
100. Kelly JM, Moir AJ, Carlson K, Yang Y, MacNeil S, Haycock JW,. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides 2006; 27: 431-437.
101. Taylor AW,. The immunomodulating neuropeptide alpha-melanocyte- stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J Neuroimmunol 2005; 162: 43-50.
102. Chang SH, Jung EJ, Lim DG, Park YH, Wee YM, Kim JH, Kim YH, Choi MY, Koo SK, Choi KD, Han DJ, Kim SC,. Anti-inflammatory action of alpha-melanocyte stimulating hormone (alpha-MSH) in anti-CD3/CD28-mediated spleen and CD4(+)CD25(-) T cells and a partial participation of IL-10. Immunol Lett 2008; 118: 44-48.
103. Rennalls LP, Seidl T, Larkin JM, Wellbrock C, Gore ME, Eisen T, Bruno L,. The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology 2010; 129: 610-619.
104. Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, Kim SM, Schnermann J, Jonassen TE, Frøkiaer J, Nielsen S, Star RA,. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008; 73: 1266-1274.
105. Montero-Melendez T, Patel HB, Seed M, Nielsen S, Jonassen TE, Perretti M,. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol 2011; 179: 259-269.
106. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T,. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 324-331.
107. Edling AE, Gomes D, Weeden T, Dzuris J, Stefano J, Pan C, Williams J, Kaplan J, Perricone MA,. Immunosuppressive activity of a novel peptide analog of α-melanocyte stimulating hormone (α-MSH) in experimental autoimmune uveitis. J Neuroimmunol 2011; 236: 1-9.
108. Gravanis A, Margioris AN,. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005; 12: 1503-1512.
109. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M,. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006; 55: 824-832.
110. Chang J, Adams MR, Clifton MS, Liao M, Brooks JH, Hasdemir B, Bhargava A,. Urocortin 1 modulates immunosignaling in a rat model of colitis via corticotropin-releasing factor receptor 2. Am J Physiol Gastrointest Liver Physiol 2011; 300: G884-G894.
111. Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, Pothoulakis C,. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin- releasing hormone receptor 2alpha. Gut 2007; 56: 1210-1217.
112. Kokkotou E, Torres D, Moss AC, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C,. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006; 177: 3355-3361.
113. Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M,. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis Rheum 2007; 56: 531-543.
114. Pérez-García S, Juarranz Y, Carriõn M, Gutiérrez-Cañas I, Margioris A, Pablos JL, Tsatsanis C, Gomariz RP,. Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide. J Cell Physiol 2011; 226: 3261-3269.
115. Poliak S, Mor F, Conlon P, Wong T, Ling N, Rivier J, Vale W, Steinman L,. Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J Immunol 1997; 158: 5751-5756.
116. Brain SD, Grant AD,. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-934.
117. Onur OE, Guneysel O, Akoglu H, Denizbasi A, Onur E,. Adrenomedullin reduces the severity of cerulein-induced acute pancreatitis. Peptides 2007; 28: 2179-2183.
118. Yang J, Wu R, Zhou M, Wang P,. Human adrenomedullin and its binding protein ameliorate sepsis-induced organ injury and mortality in jaundiced rats. Peptides 2010; 31: 872-877.
119. Kioon MD, Asensio C, Ea HK, Velard F, Uzan B, Rullé S, Bazille C, Marty C, Falgarone G, Nguyen C, Collet C, Launay JM, Cohen-Solal M, Lioté F,. Adrenomedullin(22-52) combats inflammation and prevents systemic bone loss in murine collagen-induced arthritis. Arthritis Rheum 2012; 64: 1069-1081.
120. Hayashi Y, Narumi K, Tsuji S, Tsubokawa T, Nakaya MA, Wakayama T, Zuka M, Ohshima T, Yamagishi M, Okada T,. Impact of adrenomedullin on dextran sulfate sodium-induced inflammatory colitis in mice: insights from in vitro and in vivo experimental studies. Int J Colorectal Dis 2011; 26: 1453-1462.
121. Lee EG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH,. Adrenomedullin inhibits IL-1β-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production. Inflammation 2011; 34: 335-343.
122. Kataoka Y, Miyazaki S, Yasuda S, Nagaya N, Noguchi T, Yamada N, Morii I, Kawamura A, Doi K, Miyatake K, Tomoike H, Kangawa K,. The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J Cardiovasc Pharmacol 2010; 56: 413-419.
123. Patel YC,. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198.
124. ten Bokum AM, Hofland LJ, van Hagen PM,. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw 2000; 11: 161-176.
125. Raynor K, Reisine T,. Somatostatin receptors. Crit Rev Neurobiol 1992; 6: 273-289.
126. Pintér E, Helyes Z, Szolcsányi J,. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 2006; 112: 440-456.
127. Szolcsányi J, Pintér E, Helyes Z, Oroszi G, Németh J,. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 1998; 125: 916-922.
128. Elekes K, Helyes Z, Kereskai L, Sándor K, Pintér E, Pozsgai G, Tékus V, Bánvölgyi A, Németh J, Szuts T, Kéri G, Szolcsányi J,. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. Eur J Pharmacol 2008; 578: 313-322.
129. Pintér E, Helyes Z, Németh J, Põrszász R, Pethö G, Thán M, Kéri G, Horváth A, Jakab B, Szolcsányi J,. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 142-150.
130. Helyes Z, Pintér E, Németh J, Kéri G, Thán M, Oroszi G, Horváth A, Szolcsányi J,. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br J Pharmacol 2001; 134: 1571-1579.
131. Helyes Z, Pintér E, Németh J, Sándor K, Elekes K, Szabõ A, Pozsgai G, Keszthelyi D, Kereskai L, Engström M, Wurster S, Szolcsányi J,. Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 2006; 149: 405-415.
132. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, Lamberts SW,. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest 1994; 24: 91-99.
133. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV,. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999; 29: 2454-2463.
134. Eglezos A, Andrews PV, Helme RD,. In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin. Immunol Cell Biol 1993; 71: 125-129.
135. Wiedermann CJ, Reinisch N, Braunsteiner H,. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 1993; 82: 954-960.
136. Imhof AK, Glück L, Gajda M, Lupp A, Bräuer R, Schaible HG, Schulz S,. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum 2011; 63: 2352-2362.
137. Fioravanti A, Govoni M, La Montagna G, Perpignano G, Tirri G, Trotta F, Bogliolo A, Ciocci A, Mauceri MT, Marcolongo R,. Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 1995; 21: 97-103.
138. Missotten T, van Laar JA, van der Loos TL, van Daele PL, Kuijpers RW, Baarsma GS, van Hagen PM,. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 2007; 144: 838-843.
139. Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS,. Somatostatin for Uveitic Cystoid Macular Edema (CME). Ocul Immunol Inflamm 2005; 13: 469-470.
140. van Bergeijk JD, Wilson JH, Nielsen OH, von Tirpitz C, Karvonen AL, Lygren I, Rädler A, Waldum HL, Mulder CJ, Friis S, Tefera S, Hoogkamer JF, OPUS 1 Study Group. Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). Eur J Gastroenterol Hepatol 2002; 14: 243-248.
141. Lamrani A, Tulliez M, Chauvelot-Moachon L, Chaussade S, Mauprivez C, Hagnéré AM, Vidon N,. Effects of octreotide treatment on early TNF-alpha production and localization in experimental chronic colitis. Aliment Pharmacol Ther 1999; 13: 583-594.
142. van Bergeijk JD, van Meeteren ME, Tak CJ, van Dijk AP, Meijssen MA, Wilson JH, Zijlstra FJ,. Somatostatin does not attenuate intestinal injury in dextran sodium sulphate-induced subacute colitis. Mediators Inflamm 1998; 7: 169-173.
143. Eliakim R, Karmeli F, Okon E, Rachmilewitz D,. Octreotide effectively decreases mucosal damage in experimental colitis. Gut 1993; 34: 264-269.
144. Lauer S, Daudel F, Traber DL, Nofer JR, Ertmer C, Morelli A, Van Aken H, Lange M, Rehberg S, Ellger B, Stubbe HD, Kruse C, Bone HG, Westphal M,.
145. Sener G, Cetinel S, Erkanli G, Gedik N, Yeǧen BC,. Octreotide ameliorates sepsis-induced pelvic inflammation in female rats by a neutrophil-dependent mechanism. Peptides 2005; 26: 493-499.
146. Li J, Wang R, Tang C,. Somatostatin and octreotide on the treatment of acute pancreatitis-basic and clinical studies for three decades. Curr Pharm Des 2011; 17: 1594-1601.
147. Lu Y, Yu Y, Yang M, Liu H, Li B, Xu H,. Protective effects of saizen in combination with stilamin on intestinal mucosa of a rabbit model of severe acute pancreatitis. Pancreas 2013; 42: 102-107.
148. Gonzalez-Rey E, Delgado M,. Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. Mol Cell Endocrinol 2008; 286: 135-140.
149. Markovics A, Szoke É, Sándor K, Börzsei R, Bagoly T, Kemény Á, Elekes K, Pintér E, Szolcsányi J, Helyes Z,. Comparison of the anti-inflammatory and anti-nociceptive effects of cortistatin-14 and somatostatin-14 in distinct in vitro and in vivo model systems. J Mol Neurosci 2012; 46: 40-50.
150. Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M,. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis 2007; 66: 582-588.
151. Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M,. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci U S A 2006; 103: 4228-4233.
152. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M,. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med 2006; 203: 563-571.
153. Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, Kojima M, Kangawa K, Arima T, Matsuo H, Yada T, Matsukura S,. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002; 51: 124-129.
154. van der Lely AJ, Tschöp M, Heiman ML, Ghigo E,. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457.
155. Warzecha Z, Ceranowicz P, Dembinski A, Cieszkowski J, Kusnierz-Cabala B, Tomaszewska R, Kuwahara A, Kato I,. Therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis in rats. J Physiol Pharmacol 2010; 61: 419-427.
156. Granado M, Priego T, Martín AI, Villanúa MA, Lõpez-Calderõn A,. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 2005; 288: E486-E492.
157. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M,. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008; 180: 8369-8377.
158. Deboer MD,. Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations. Int J Pept 2011; 2011: 189242.
159. Lang R, Gundlach AL, Kofler B,. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007; 115: 177-207.
160. Zhang L, Yu W, Schroedter I, Kong J, Vrontakis M,. Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced MS mouse model. PLoS ONE 2012; 7: e33901.
161. Talero E, Sánchez-Fidalgo S, Calvo JR, Motilva V,. Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul Pept 2007; 141: 96-104.
162. Matkowskyj KA, Nathaniel R, Prasad R, Weihrauch D, Rao M, Benya RV,. Galanin contributes to the excess colonic fluid secretion observed in dextran sulfate sodium murine colitis. Inflamm Bowel Dis 2004; 10: 408-416.
163. Bhandari M, Thomas AC, Hussey DJ, Li X, Jaya SP, Woods CM, Schloithe AC, Mayne GC, Carati CJ, Toouli J, Ormandy CJ, Saccone GT,. Galanin mediates the pathogenesis of cerulein-induced acute pancreatitis in the mouse. Pancreas 2010; 39: 182-187.
164. Bhandari M, Kawamoto M, Thomas AC, Barreto SG, Schloithe AC, Carati CJ, Toouli J, Saccone GT,. Galanin receptor antagonist m35 but not m40 or c7 ameliorates cerulein-induced acute pancreatitis in mice. Pancreatology 2010; 10: 682-688.
165. Barreto SG, Bazargan M, Zotti M, Hussey DJ, Sukocheva OA, Peiris H, Leong M, Keating DJ, Schloithe AC, Carati CJ, Smith C, Toouli J, Saccone GT,. Galanin receptor 3-a potential target for acute pancreatitis therapy. Neurogastroenterol Motil 2011; 23: e141-e151.
166. Schmidhuber SM, Starr A, Wynick D, Kofler B, Brain SD,. Targeted disruption of the galanin gene attenuates inflammatory responses in murine skin. J Mol Neurosci 2008; 34: 149-155.
167. Zadina JE, Hackler L, Ge LJ, Kastin AJ,. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502.
168. Hackler L, Zadina JE, Ge LJ, Kastin AJ,. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997; 18: 1635-1639.
169. Wu SY, Dun SL, Wright MT, Chang JK, Dun NJ,. Endomorphin-like immunoreactivity in the rat dorsal horn and inhibition of substantia gelatinosa neurons in vitro. Neuroscience 1999; 89: 317-321.
170. Jessop DS, Richards LJ, Harbuz MS,. Opioid peptides endomorphin-1 and endomorphin-2 in the immune system in humans and in a rodent model of inflammation. Ann N Y Acad Sci 2002; 966: 456-463.
171. Pierce TL, Grahek MD, Wessendorf MW,. Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport 1998; 9: 385-389.
172. Straub RH, Wolff C, Fassold A, Hofbauer R, Chover-Gonzalez A, Richards LJ, Jessop DS,. Antiinflammatory role of endomorphins in osteoarthritis, rheumatoid arthritis, and adjuvant-induced polyarthritis. Arthritis Rheum 2008; 58: 456-466.
173. Alexander SP, Mathie A, Peters JA,. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 2011; 164 (Suppl. 1): S1-324.